Roche abandons two Huntington's drug candidates
Roche abandons two Huntington's drug candidates Phil.Taylor Fri, 10/07/2026 - 08:43
Read the full articleYou might also wanna read
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaite
Roche ends two Ionis-partnered Huntington's drugs after trial failures
Roche has discontinued two Huntington's disease therapies developed with Ionis Pharmaceuticals after one failed to slow disease progression
Roche Aktie: Neue Alzheimer-Daten im Juli
Roche geht einen ungewöhnlichen Weg in der Alzheimer-Forschung. Der Schweizer Pharmakonzern verknüpft seine Diagnostik-Sparte mit der Entwic
Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
Nature, Published online: 30 June 2026; doi:10.1038/s41586-026-10816-w Retraction Note: NSD2 targeting reverses plasticity and drug resistan
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Comments
Sign in to join the conversation.
No comments yet. Be the first.